Stop Alzheimer’s before it starts.
Early detection, predictive risk and preventive therapy, funded by the savings they create.
It starts decades before symptoms.
For up to two decades, the brain looks fine. That’s our window.
Schematic
One blood draw.
Phosphorylated tau, NfL and Aβ isoforms from a routine sample.
- p-tau Phosphorylated tau
- NfL Neurofilament light
- Aβ42/40 Amyloid-β isoforms
~23×cheaper than PET
Blood test$350
PET scan$8,000
about $7,650 saved per test
Every test sharpens the signal.
A Bayesian model re-estimates risk after each repeat test.
Illustrative
It starts from APOE ε4, family history and metabolic markers.
Clear it before it builds.
ZNT-GLP1: a GLP-1–based therapy, investigational, with three mechanisms.
Investigational · illustrative model
- Inflammation ↓
- Mitochondria stabilised
- Glymphatic clearance ↑
64%
of untreated burden at year 20
dA/dt = α·f(risk) − β_nat·A − β_glp·A
Prevention that pays for itself.
AD Prevention Bonds tie investor returns to documented healthcare savings.
- Target yield
- 5–8%
- Term
- 5–8 yr
The stakes
$1T+a year on US dementia care, heading toward $3T.
US, per 100 people
8%biologically affected.
2%show symptoms.
Globally, the cost passes $2T by 2030.
Researchers. Clinicians. Data scientists. Investors.
From Tel Aviv’s biotech corridor, where research meets finance.
Or write to info@zentara.com
Read the full thesis.
Detection, prevention and the finance to fund it, in nine chapters.